Docon Technologies Sells 9.9% Stake in Thyrocare for ₹986 Crore

Docon Technologies, a key promoter of Thyrocare Technologies Ltd, has divested a 9.9% stake in the diagnostics firm, generating ₹986 crore from the transaction. This significant sale took place through multiple block and bulk deals across the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) on Thursday.

The transaction involved the sale of 1,57,69,696 equity shares. Of these, over 1.31 crore shares were sold via block deals, while an additional 10 lakh shares were handled through bulk deals on the NSE. The BSE saw 16.01 lakh shares change hands through a bulk deal. The shares were sold within a price range of ₹624 to ₹631.71 each.

Impact on Shareholding and Market Response

Following this transaction, Docon Technologies' stake in Thyrocare Technologies decreased from 60.92% to 51.02%. The stake sale attracted a diverse group of investors, including institutional investors, insurance companies, and global entities. Notable buyers included HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Insurance firms like Kotak Mahindra Life Insurance and Tata AIA Life Insurance also participated, alongside global investors such as Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments, and the Kuwait Investment Authority.

In response to the transaction, Thyrocare Technologies' share price saw a rise, closing 3% higher at ₹621.95 on the NSE and over 2% higher at ₹622 on the BSE by Friday. This market reaction underscores investor confidence in the company despite the reduction in promoter holding.

Historical Context and Future Prospects

This recent stake sale follows a previous transaction in October last year when Docon offloaded a 10% stake in Thyrocare for ₹667 crore. Thyrocare Technologies, a prominent player in the diagnostics sector, continues to attract significant investor interest due to its robust business model and market position.

While the latest sale reduces Docon's shareholding, it also opens avenues for diverse institutional participation, which could be beneficial for Thyrocare's strategic growth and expansion plans. The diagnostics industry in India has been witnessing rapid growth, and Thyrocare's ability to maintain investor interest highlights its potential for continued success.